UBS Lux Equity Fund Biotech USD vs Nordnet Kehittyvät Markkinat Indeksi

UBS Lux Equity Fund Biotech USD vs Nordnet Kehittyvät Markkinat Indeksi

1. UBS Lux Equity Fund Biotech USD

  • Security

    UBS Lux Equity Fund Biotech USD P-acc

  • Fee

    2.25%

  • ISIN

    LU0069152568

  • Holdings

    10

2. Nordnet Kehittyvät Markkinat Indeksi

  • Security

    Nordnet Kehittyvät Markkinat Indeksi

  • Fee

    0.39%

  • ISIN

    IE00BMTD2R45

  • Holdings

    16

  • Number of owning funds

    2

Fund Holdings

We have information about 14 holdings in UBS Lux Equity Fund Biotech USD, where the largest holding is Regeneron Pharmaceuticals (10.04), followed by Vertex (9.35) and Moderna (9.21). In comparison with Nordnet Kehittyvät Markkinat Indeksi, we have 23 holdings where TSMC is the largest holding (15.52), followed by Tencent (8.82) and Alibaba Group Holding Ltd (5.44).

All Holdings

Here we compare the holdings in UBS Lux Equity Fund Biotech USD and Nordnet Kehittyvät Markkinat Indeksi.

UBS Lux Equity Fund Biotech USD Nordnet Kehittyvät Markkinat Indeksi
1. Regeneron Pharmaceuticals Inc
10.04 %
1. Taiwan Semiconductor Manufacturing Company
Taiwan
15.52 %
2. Vertex Pharmaceuticals Inc
9.35 %
2. Tencent Holdings Ltd
China
8.82 %
3. Moderna Inc
9.21 %
3. Alibaba Group Holding Ltd
China
5.44 %
4. Alnylam Pharmaceuticals Inc
6.96 %
4. HDFC Bank Ltd ADR
India
2.86 %
5. AbbVie Inc
USA
5.53 %
5. Reliance Industries Ltd
India
2.25 %
6. Gilead Sciences Inc
USA
4.66 %
6. China Construction Bank Corp Class H
China
1.76 %
7. Amgen Inc
4.3 %
7. MediaTek Inc
Taiwan
1.43 %
8. BioNTech SE
4.13 %
8. Infosys Ltd
India
1.31 %
9. Karuna Therapeutics Inc
3.75 %
9. BYD Co Ltd Class H
China
1.3 %
10. Royalty Pharma Plc
3.37 %
10. Bharti Airtel Ltd
India
1.26 %
- 11. Naspers Ltd
South Africa
0.99 %
- 12. NetEase ADR
China
0.92 %
- 13. Itau Unibanco Banco SA
Brazil
0.74 %
- 14. Axis Bank Ltd
India
0.71 %
- 15. Baidu Inc
0.56 %
- 16. KB Financial Group Inc
South Korea
0.53 %

The list of fund holdings was last updated on June 6, 2025.